Business Wire

Results of Global Phase III Study with Chugai's HEMLIBRA® for Hemophilia A Without Inhibitors Published in the New England Journal of Medicine

Del

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) today announced that results of the HAVEN 3 study (NCT02847637), the global phase III study evaluating hemophilia A treatment, HEMLIBRA® (generic name: emicizumab [genetical recombination]), were published in the 30 August 2018 issue of the New England Journal of Medicine (NEJM).
Article: https://www.nejm.org/doi/full/10.1056/NEJMoa1803550
Quick video summary by NEJM: https://www.nejm.org/do/10.1056/NEJMdo005333/full/

The study evaluated the efficacy and safety of HEMLIBRA subcutaneous injection, once a week and once every two weeks, in people with hemophilia A (12 years of age or older) without inhibitors to factor VIII. Detailed results of the study were presented at the World Federation of Hemophilia (WFH) 2018 World Congress held in Glasgow, Scotland on May 21, 2018.

“This is the third time that the clinical data of HEMLIBRA have been published in NEJM, following the results of the phase I/II studies and the first phase III study. It demonstrates a high medical value that the drug may bring to the treatment of hemophilia A,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “We are committed to deliver HEMLIBRA which has been created with our proprietary bispecific antibody technologies, as a new treatment option to people with hemophilia A without inhibitors as early as possible in cooperation with Roche.”

In May 2018, HEMLIBRA was launched in Japan for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors. An application for an additional indication of the treatment of hemophilia A without factor VIII inhibitors has been filed in April in Japan. Applications for the same additional indication have also been filed in the United States and Europe. In the U.S., the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation in April, and Priority Review in June, for this line extension. In Europe, the review by the EU Committee for Medicinal Products for Human Use (CHMP) is ongoing.

Reference

Chugai Presents Results of Two Pivotal Phase III Studies for its Bispecific Antibody HEMLIBRA at WFH 2018 (Press release issued on May 21, 2018)
https://www.chugai-pharm.co.jp/english/news/detail/20180521160000.html

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totalled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.

Trademarks used or mentioned in this release are protected by law.

Contact information

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Tomoko Shimizu
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Janssen Seeks Expanded Use of IMBRUVICA®▼ (ibrutinib) in Two Indications in Europe14.11.2018 14:23Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two Type II variation applications to the European Medicines Agency (EMA) seeking approval for the expanded use of IMBRUVICA® (ibrutinib). One application seeks to include use of ibrutinib in combination with obinutuzumab in previously untreated adults with chronic lymphocytic leukaemia (CLL) and to add long-term follow-up data from the existing label studies RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115). The second is for use of ibrutinib plus rituximab for the treatment of previously untreated and relapsed/refractory adults with Waldenström's macroglobulinemia (WM). “Today’s news brings us one step closer to potentially offering ibrutinib in new combinations for patients where unmet needs still persist,” said Dr. Catherine Taylor, Haematology Therapy Area Lead, Europe, Middle East and Africa (EMEA), Janssen-Cilag Limited. “Ibrutinib continues to demonstrate clinical benefit over the long

ResMed Completes Acquisition of MatrixCare14.11.2018 14:05Pressemelding

ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has completed its $750 million acquisition of Minnesota-based MatrixCare, a leader in software solutions for more than 15,000 providers across skilled nursing, life plan communities, senior living and private duty. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005282/en/ These care settings are complementary to ResMed’s other SaaS offerings in home medical equipment, home health and hospice, delivered through Brightree and HEALTHCAREfirst, acquired by ResMed in April 2016 and July 2018, respectively. ResMed will drive an integrated ecosystem of solutions across these platforms to maintain single-patient records across multiple care settings, generate analytics and insights that can be applied to individuals and whole populations, and streamline processes acr

REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 201814.11.2018 13:30Pressemelding

Today, the Board of Directors of Reply [MTA, STAR: REY] approved the results as at 30 September 2018. In the first nine months of the year, the Group has recorded a consolidated turnover of €754.4 million, with an increase of 15.8% compared to €651.3 million at September 2017. Consolidated EBITDA to September was €101.2 million (€89.8 million at September 2017) with an EBIT of €91.4 million (€81.7 million at September 2017). Pre-tax profit amounted to €96.3 million, which represents an increase of 22.4% compared to the same period of 2017. For the third quarter of 2018 (July-September), the Group registered a consolidated turnover of €256.3 million (€209.7 million in 2017), an EBITDA of €32.9 million (€28.0 million in 2017), an EBIT of €29.3 million (€24.7 million in 2017) and a pre-tax profit of €32.1 million (25.3 million in 2017). As at 30 September 2018, the Group's net financial position was positive for €56.3 million, improving compared to €50.2 million registered on June 30, 201

Blackjack Booster Lands at Intertops Poker14.11.2018 13:20Pressemelding

Intertops Poker is boosting player winnings this weekend with an extra 10% on the Lucktap games Blackjack, Face Up 21, Double Draw Blackjack and Perfect Pairs Blackjack. The promotion is being offered exclusively through the Intertops Poker software, and will run from Friday 16th November to Sunday 18th November. To access the promotion, players log into the Intertops Poker software and click the Casino tab in the top right hand corner. They then chose from one of the Lucktap games (Blackjack, Face Up 21, Double Draw Blackjack and Perfect Pairs Blackjack) offered and any winning bets will be increased by 10%. The additional 10% winnings will be shown as a bonus balance and will be released once the x15 wagering requirement has been met. The maximum prize that can be won is $250. The poker manager at Intertops Poker, said: “Here at Intertops Poker we are always looking to provide our players with even more value, which is why we are boosting all winnings on our Lucktap games by 10% this

Corsearch Announces Acquisition of Yellow Brand Protection14.11.2018 13:00Pressemelding

Corsearch Inc. and its related entities, a trademark and domain solutions leader, is pleased to announce the acquisition of Yellow Brand Protection AB of Sweden, a leading global provider of online anti-counterfeiting and brand protection services. The acquisition, effective immediately, solidifies and further expands Corsearch’s full service brand protection offering for clients and brands globally . The facts speak for themselves in this industry – In 2018, online sales will approach $3 trillion U.S. Dollars, with one in four online purchases involving pirated goods. Online IP infringement is a continued and increasingly expanding challenge for all brands, as e-commerce growth continues at record speed and digital marketing becomes a core business strategy. Corsearch, founded in 1949, provides industry-leading brand establishment and protection services for trademark and brand professionals in over 60 countries on five continents. Yellow Brand Protection, founded in 2010, provides br

PEI-Genesis Approved as Category C Distributor for All Conesys Product Lines14.11.2018 11:15Pressemelding

PEI-Genesis, the world’s fastest assembler of precision connectors, has been approved as a Category C Distributor for all Conesys product lines. PEI-Genesis will be assembling all government approved Mil-Circular connector product lines manufactured by Conesys at the company’s South Bend, IN facility. “The addition of Conesys Mil-Circular connectors gives global, value-added access to all customers and adds to the breadth of Conesys’ offerings,” said Peter Austin, PEI-Genesis’s Senior Vice President of Manufacturing, Product Management, Marketing, & Training. “The new partnership will give Conesys access to our award-winning service and largest available-to-sell connector inventory.” PEI-Genesis has inventory to assemble Conesys connectors now, and will be able to assemble over 50,000 military connector part numbers from Conesys inventory very soon. Product families being assembled by PEI-Genesis for Conesys include the MIL-DTL-38999, MIL-DTL-26482, MIL-DTL-83723, and MIL-DTL-26500. “W